Oblique Therapeutics scientific publications.

Scientific publications

Publications regarding AbiProt®:

Trkulja C.L. et al; Rational Antibody design for Undruggable Targets using Kinetically Controlled Biomolecular Probes. Science Advances 16 Apr 2021; Vol. 7, no. 16, eabe6397
https://advances.sciencemag.org/content/7/16/eabe6397.abstract
Trkulja C.L. et al; Probing Structure and Function of Ion Channels Using Limited Proteolysis and Microfluidics. J. Am. Chem. Soc. 2014; 136, 42, 14875–14882
https://pubs.acs.org/doi/abs/10.1021/ja507285w

Highlighted programs in pipeline

KRAS: a portfolio of aG13D, aG12D and aG12V antibodies intended for treatment of aggressive cancer

Oblique Therapeutics has developed a pipeline of mutant selective aKRAS mAbs where the most advanced program targeting the KRAS G13D mutation has shown efficacy in a colorectal cancer xenograft model.

TRPV1: Intended for treatment of pain

Oblique Therapeutics has developed high affinity, stimuli-selective antibodies against the pain receptor TRPV1 in order to maximize pain relief and circumvent side effects.